elvitegravir + cobicistat + emtricitabine + tenofovir alafenamide + atazanavir

This is a **combination of five antiretroviral drugs**: elvitegravir (an HIV-1 integrase strand transfer inhibitor), cobicistat (a pharmacokinetic enhancer serving as a CYP3A inhibitor), emtricitabine (a nucleoside reverse transcriptase inhibitor), tenofovir alafenamide (a nucleotide reverse transcriptase inhibitor prodrug), and atazanavir (an HIV-1 protease inhibitor). While fixed-dose combinations of the first four (e.g., Genvoya) exist and fixed-dose combinations of cobicistat and atazanavir are approved and marketed (e.g., Evotaz), **this specific five-drug combination does not have an established fixed-dose product or unique marketed brand in major regulatory regions**. However, all components are used for the **treatment of HIV-1 infection** as part of combination antiretroviral therapy regimens.